New Haven, CTNCT06067555Now EnrollingIRB Ready

Vaccine Reaction Clinical Trial in New Haven, CT

Access cutting-edge vaccine reaction treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Yale University

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access vaccine reaction specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related vaccine reaction treatment provided free

Apply for This New Haven Location

Check if you qualify for this vaccine reaction clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Vaccine Reaction Study in New Haven

The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination in healthy individuals. The intervention involves intradermal administration of an FDA-approved intramuscular seasonal influenza vaccine, using an FDA-approved device MicronJet. Investigators will measure antibody titers, cell subtypes, and multi-omic profiles, by collecting skin and peripheral blood at baseline and at several time points after vaccination. The primary objective is to identify baseline correlates of immune response in the skin and peripheral blood to the seasonal influenza vaccine. The investigators secondary goals are to describe the inflammatory response in the skin over time.

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study, as well as have deidentified samples and data stored for future research.
Able to proficiently speak, read, and write English.
Male or female, aged 18-40 years old at time of initial enrollment a. Participant is allowed to participate in subsequent influenza seasons even if they will be \>40 years old.
In good general health as evidenced by medical history Individuals meeting any of the following criteria will be excluded from study participation:
CBC with differential, lymphocyte phenotyping with T, B, and natural killer cells (TBNK), complete metabolic panel, anti-CMV immunoglobulin (Ig) G and IgM, and/or anti-Epstein-Barr virus (EBV) antibody panel values outside of the Yale Department of Laboratory Medicine normal reference ranges and deemed clinically significant by the PI at the time of screening.
Positive result for anti-HIV 1/2 antibody screening at the time of screening.
Prior receipt of a current seasonal influenza vaccine (for the season of participation).
History of allergy or hypersensitivity to any components of the study vaccine (e.g., egg protein).
History of severe reactions to vaccines.
Use of an oral glucocorticoid within the past 30 days.
Receipt of a live-attenuated vaccine within the past 3 months.
Receipt of any experimental vaccine.
Receipt of any other type of vaccine (non-live and non-experimental, e.g., tetanus, diphtheria, and pertussis \[TDaP\]) within the past 3 months.
Planned vaccination before day 100 after study vaccination.
Current or recent use (within the past 90 days) of immunoglobulin therapy.
Surgery within the past 8 weeks, or planned surgery before day 28.
Current (within the past 30 days) treatment for active malignancy.
Cancer chemotherapy in the past 2 years.
Administration of any blood products within 90 days of the screening, or planned administration before day 100.
History of parasitic, amebic, fungal, or mycobacterial infections within the past 1 year, with the exception of tinea pedis and onychomycosis.
History of autoimmune or autoinflammatory disease. a. In particular skin-related (i.e. psoriasis, lichen planus, lupus, neutrophilic dermatoses, atopic dermatitis)
History of keloids
History of a bleeding disorder.
Current use (within the past 30 days) of illicit drugs (per subject report), with the exception of marijuana.
Current alcohol use disorders (criteria per Diagnostic and Statistical Manual of Mental Disorders, fifth edition), within the past 30 days.
Serious, ongoing, uncontrolled infection within the past 30 days as per the judgement of the PI.
History of Guillain-Barre syndrome (GBS).
Known or suspected immunodeficiency within 1 year, including documented HIV infection.
Pregnancy or planning to become pregnant during the study period. (Women of childbearing potential must have a negative urine or serum pregnancy test at screening.)
Presence of conditions that, in the judgment of the PI, may put the individual at undue risk or compromise the scientific objectives of the study. Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies. Consideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the PI. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the PI.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT06067555) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Vaccine Reaction Treatment Options in New Haven, CT

If you're searching for vaccine reaction treatment options in New Haven, CT, this clinical trial (NCT06067555) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced vaccine reaction specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all vaccine reaction clinical trials near you to find additional studies recruiting in your area.

More Vaccine Trials in New Haven, CT

See all vaccine clinical trials recruiting in New Haven — not just this study.

Browse Vaccine Trials in New Haven →

Browse More Trials by Condition

Vaccine TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT